Calcific Aortic Valve Stenosis – Kardigan ATA-301

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.

Key Inclusion Criteria:

• Adult male or female at least 50 years of age
• Has moderate CAVS as defined by:
  • An AVA of ≥1 cm2 to ≤1.50 cm2
  • An AVC score between ≥600 to 1200 Agatston units (AU) for women and between ≥600 to 2000 AU for men
• Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Core Laboratory
• Can perform Cardiopulmonary Exercise Testing (CPET)
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.